For three weeks leading up to the Indy 500, Testicular Cancer Awareness Foundation and Fennec Pharmaceuticals brought the Indy’s Nuts campaign to Indianapolis Motor Speedway. Through partnerships with Alex Singleton, Jack Harvey, INVST, and Dreyer & Reinbold Racing, the campaign sparked conversations about testicular cancer, early detection, hearing loss caused by chemotherapy, and life after cancer while reaching thousands of race fans throughout race month.
Read MoreTony discusses using MicroRNA 371, an emerging blood test showing major promise in detecting active germ cell tumors, along with Signatera, a personalized circulating tumor DNA (ctDNA) test designed to monitor for residual disease and recurrence. He shares what it was like balancing traditional surveillance methods like CT scans and tumor markers with these newer technologies, and how the uncertainty of recurrence can weigh heavily on survivors mentally and emotionally.
Read MoreDrawing from her professional experience as an LMFT, Renee explains how cancer affects far more than physical health. The conversation explores the fear, uncertainty, anxiety, and identity shifts that often follow a diagnosis, especially for men who may feel pressure to stay strong or avoid emotional vulnerability. She also shares practical insight into how couples can communicate more effectively during treatment and recovery, even when both partners are struggling in different ways.
Read MoreIn partnership with Fennec Pharmaceuticals, the Testicular Cancer Awareness Foundation welcomed physicians, audiologists, and other leaders in the testicular cancer space to Indianapolis for the inaugural TCAF Indy 500 Educational Event. The day combined meaningful education around survivorship and hearing health with unique networking opportunities surrounding Fast Friday at the Indianapolis Motor Speedway.
Read MoreDylan began treatment for a non-seminoma germ cell tumor with EP chemotherapy, but midway through, his condition took a devastating turn. What started as standard cancer treatment escalated into severe complications, including sepsis and gangrene, leaving him hospitalized in critical condition. At one point, his family was called in to say goodbye.
Read MoreLuke opens up about the physical toll of treatment, including fatigue and side effects, as well as the mental challenges that came with such an unexpected turn. From scan anxiety to continuing therapy during treatment, he shares how he navigated both the data-driven decisions and the emotional weight of cancer.
Read MoreBeyond the event itself, the episode reinforces the mission: raising awareness and promoting early detection. Listeners are reminded of the importance of monthly testicular self-exams, common symptoms, and how early diagnosis can lead to high cure rates, especially when detected early.
More than anything, this episode is about community and turning awareness into action to provide meaningful support to those affected by testicular cancer.
Read MoreThis episode highlights the importance of recognizing testicular cancer symptoms, advocating for your health, and understanding that survivorship is about more than just treatment—it’s about rebuilding physically, mentally, and spiritually.
Read MoreBeyond treatment, this episode explores the importance of being treated at high-volume centers, avoiding overtreatment, and understanding the long-term effects of both surgery and chemotherapy. Dr. Daneshmand also discusses the status and future of MicroRNA 371 biomarker testing.
Read MoreOsvaldo walks through the shock of hearing “you have cancer,” undergoing an orchiectomy, and waking up to learn that the his testicle had been completely removed. He candidly describes the emotional reality of losing a testicle, the confusion around what doctors were removing, and the relief of finally being free from the constant pain after surgery. His story is an important reminder that testicular cancer symptoms can include a lump, swelling, heaviness, and persistent back pain — and that early detection can save your life.
Read MoreAt the 2025 Testicular Cancer Conference, Dr. Lindsay Frazier discussed how international collaboration is accelerating research for testicular cancer and other germ cell tumors through the Malignant Germ Cell Tumor International Consortium (MaGIC).
Read MoreDr. Feldman began by reflecting on the history of testicular cancer treatment and the dramatic shift brought about by cisplatin-based chemotherapy. Key takeaways included:
Before cisplatin, metastatic testicular cancer was often fatal, with most patients not surviving
The introduction of cisplatin is considered one of the greatest medical advances of the 20th century
Survival rates for metastatic disease improved from roughly 20% to nearly 80%
While highly effective, cisplatin is associated with significant short- and long-term side effects, making toxicity reduction an ongoing priority